IVABRADINE GPPL ivabradine (as hydrochloride) 5 mg tablet blister pack

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

ivabradine hydrochloride, Quantity: 5.39 mg (Equivalent: ivabradine, Qty 5 mg)

Commercializzato da:

Arrotex Pharmaceuticals Pty Ltd

Forma farmaceutica:

Tablet, film coated

Composizione:

Excipient Ingredients: lactose monohydrate; maize starch; colloidal anhydrous silica; maltodextrin; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000

Via di somministrazione:

Oral

Confezione:

56, 14

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Treatment of chronic stable angina Symptomatic treatment of chronic stable angina due to atherosclerotic coronary artery disease in patients with normal sinus rhythm and heart rate at or above 70 bpm, who are unable to tolerate or have a contraindication to the use of beta-blockers, OR in combination with atenolol 50mg once daily when angina is inadequately controlled.,Treatment of chronic heart failure Treatment of symptomatic chronic heart failure of NYHA Classes II or III and with documented left ventricular ejection fraction (LVEF) ? 35% in adult patients in sinus rhythm and with heart rate at or above 77 bpm, in combination with optimal standard chronic heart failure treatment.

Dettagli prodotto:

Visual Identification: Ivabradine 5 mg is light salmon, capsule shape (8.25 mm x 4 mm), biconvex film-coated tablet scored on one side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Stato dell'autorizzazione:

Registered

Data dell'autorizzazione:

2018-01-11